Episode 49
Biotech Hangout
00:00
The Bottleneck in the Early Stage Capital Market
Zachary Kuchins: As the only speaker here who actually went through YC and Sam Altman was my group partner back in the day, I had a few thoughts here. How are they going to differentiate in such a flooded market where there's a ton of early stage capital? For whom that pitch is going to appeal?" Alex Federation: Who exactly are these founders that are going to like Curie Bio's pitch? Because at the end of the day,. I'm in phase three managing as a corresponds or managing a trial and I didn't have any experience as a first-time founder doing this."
Transcript
Play full episode
